Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 17;15(11):1423.
doi: 10.3390/ph15111423.

Antithymocyte Globulin Plus Post-Transplant Cyclophosphamide Combination as an Effective Strategy for Graft-versus-Host Disease Prevention in Haploidentical Peripheral Blood Stem Cell Transplantation for Children with High-Risk Malignancies

Kang-Hsi Wu  1   2 , Te-Fu Weng  1 , Ju-Pi Li  1   3 , Yu-Hua Chao  1   2   4
Affiliations

Antithymocyte Globulin Plus Post-Transplant Cyclophosphamide Combination as an Effective Strategy for Graft-versus-Host Disease Prevention in Haploidentical Peripheral Blood Stem Cell Transplantation for Children with High-Risk Malignancies

Kang-Hsi Wu et al. Pharmaceuticals (Basel). .

Abstract

Haploidentical hematopoietic stem cell transplantation using post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis has emerged as a valid alternative transplant strategy for patients lacking a suitable HLA-matched related donor. The high risk of severe GVHD remains the major clinical challenge in this setting. The addition of antithymocyte globulin (ATG) in PTCy-based regimens for GVHD reduction in haploidentical hematopoietic stem cell transplantation is rational and was reported in adult series. However, its feasibility is unknown in pediatric patients. Here, we firstly describe our experience of 15 consecutive children with high-risk malignancies receiving haploidentical peripheral blood stem cell transplantation using ATG plus PTCy for GVHD prophylaxis. Only three patients developed grade 1-2 acute GVHD, limited to skin. No grade 3-4 acute GVHD and chronic GVHD were observed. Viral reactivations were frequently seen but manageable. Six patients relapsed, as the main cause of death in our series. None died from events related to GVHD. Our data suggest that ATG plus PTCy is an effective strategy for GVHD prevention in haploidentical peripheral blood stem cell transplantation and is feasible in children with high-risk malignancies.

Keywords: antithymocyte globulin; children; graft-versus-host disease; haploidentical transplantation; post-transplant cyclophosphamide.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Gragert L., Eapen M., Williams E., Freeman J., Spellman S., Baitty R., Hartzman R., Rizzo J.D., Horowitz M., Confer D., et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N. Engl. J. Med. 2014;371:339–348. doi: 10.1056/NEJMsa1311707. - DOI - PMC - PubMed
    1. Luznik L., Jalla S., Engstrom L.W., Iannone R., Fuchs E.J. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98:3456–3464. doi: 10.1182/blood.V98.12.3456. - DOI - PubMed
    1. Luznik L., O’Donnell P.V., Symons H.J., Chen A.R., Leffell M.S., Zahurak M., Gooley T.A., Piantadosi S., Kaup M., Ambinder R.F., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transpl. 2008;14:641–650. doi: 10.1016/j.bbmt.2008.03.005. - DOI - PMC - PubMed
    1. Jaiswal S.R., Chakrabarti S. Haploidentical transplantation in children with acute leukemia: The unresolved issues. Adv. Hematol. 2016;2016:3467672. doi: 10.1155/2016/3467672. - DOI - PMC - PubMed
    1. Portier D.A., Sabo R.T., Roberts C.H., Fletcher D.S., Meier J., Clark W.B., Neale M.C., Manjili M.H., McCarty J.M., Chung H.M., et al. Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients. Bone Marrow Transpl. 2012;47:1513–1519. doi: 10.1038/bmt.2012.81. - DOI - PMC - PubMed